INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10531884
Filing Date	2006-04-11
First Named Inventor	David HAIGH
Art Unit	1626
Examiner Name	Cheng, Karen
Attorney Docket Number	PG4630USw

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6576712 cannot read		1995-01-03	Alig L. et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
/KC/	1	9929705	WO	A2	1999-06-17	Glycomed Incorporated		☐
/KC/	2	99/37304	WO	A1	1999-07-29	RHONE-POULENC RORER PHARMACEUTICALS INC		☐
/KC/	3	2002/44188	WO	A2	2002-06-06	SCIOS INC.		☐

/Karen Cheng/ 07/17/2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10531684
	Filing Date	2006-04-11
	First Named Inventor	David HAIGH
	Art Unit	1626
	Examiner Name	Cheng, Karen
	Attorney Docket Number	PG4890USw

/KC/	4	96/33170	WO	A1	1996-10-24	CIBA-GEIGY AG		☐
/KC/	5	2004037818	WO	A1	2004-05-06	Glaxo Group Limited		☐
/KC/	6	03037893	WO		2003-05-08			☐
/KC/	7	03037895	WO	A1	2003-05-08	Glaxo Group Limited		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[3]
/KC/	1	SATO ET AL; Heterocycles; 1994; 37/1; 245-248;	☐
/KC/	2	P. DE CAPRARIIS, G DE MARTINO, E. ABIGNENTE, P AVARA, L MAYO; Pyrrolo[1,4]benzodiazepines. IV Synthesis of E- and Z-5,11-Dioxo-11a-ethoxycarbonyl-2-ethylidine-1,2,3,10,11,11a-hexahydro-5Hpyrrolo[2,1-c][1,4] benzodiazepine; J. Heterocyclic Chem.; Jan 89; 26; 1023-1027;	☐
/KC/	3	GARDINER, JAMES ET AL; Synthesis and solid state conformation of phenylalanine mimetics constrained in a proline-like conformation; Organic & Biomolecular Chemistry; 27 July 2004; 2(16); 2365-2370;	☐
/KC/	4	IKEDA M., ET AL.; Synthesis of tricyclic nitrogen-containing heterocycles by palladium-catalyzed cyclization of 2-alkenyl-n-(o-iodobenzoyl)- and 2-alkenyl-n-(o-iodophenylacetyl)-pyrrolidines; Heterocycles; 1998; 42; pgs. 155-158;	☐
/KC/	5	CONFALONE P.N., ET AL.; Design and synthesis of potential DNA cross-linking reagents based on the anthramycin class of minor groove binding compounds; J. Org. Chem.; 1988; 53; pgs. 482-487;	☐

/Karen Cheng/ 07/17/2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10531684
	Filing Date	2006-04-11
	First Named Inventor	David HAIGH
	Art Unit	1626
	Examiner Name	Cheng, Karen
	Attorney Docket Number	PG4690USw

/KC/	6	AUG L., ET AL.; Low molecular weight, non-peptide fibrinogen receptor antagonists; J. Med. Chem.; 1992; 35; pgs. 4393-4407;	☐
/KC/	7	PADWA A., ET AL.; Transmutations of 1,3-dipoles. The conversion of a-diazo ketones into azomethine ylides via carbonyl ylides; J. Am. Chem. Soc.; 1992; 114; pgs. 593-601;	☐
/KC/	8	CULBERTSON T.P., ET AL.; Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships; J. Med. Chem.; 1990; 33; pgs. 2270-2275;	☐
/KC/	9	CROOKS, P.A., ET AL.; Synthesis of 5-hydroxy- and 5,6-dihydroxy-derivatives of spiro[indane-2,2'-pyrrolidine], rigid analogues of tyramine and dopamine respectively; Journal of the Chemical Society, Perkins Transactions 1; 1978; 11; pgs. 2719-2726;	☐
/KC/	10	DE MARTINO G., ET AL.; La Reazione Tra 2-Nitrobenzoilaminomalonato Ed Aldeide Aorilica Per LA Sintesi Di Composti A Struttura Pirrolo[2,1-c] [1,4]Benzodiazepinica (english summary only); Farmaco Ed Sc.; 1976; 31(11); pgs. 786-790;	☐
/KC/	11	IKEDA ET AL; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry; 1997; 22; 3339-3344;	☐
/KC/	12	SATO ET AL; Journal of the Chemical Society, Perkin Transactions 1; 1995; 14; 1801-1809;	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Karen Cheng/	Date Considered	07/17/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.